이식 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of transplantation Market

The global transplantation market comprises medical procedures and products related to the transplantation of organs and tissues, including kidneys, liver, heart, lungs, cornea, skin, bones, and tendons. Transplantation plays a critical role in saving lives affected by organ failure caused by chronic diseases, trauma, poisoning, blood loss, leukemia, sepsis, and other acute conditions. Rising demand for transplant procedures, coupled with increasing awareness and technological innovation, is significantly driving the market's growth.

Market Size and Forecast

According to Fortune Business Insights, the global transplantation market was valued at USD 11.93 billion in 2025. It is projected to grow to USD 13.01 billion in 2026 and further expand to USD 28.57 billion by 2034, registering a CAGR of 10.33% during the forecast period (2026-2034).

North America dominated the market with a 42.29% share in 2025, supported by advanced healthcare infrastructure, favorable reimbursement policies, and a high number of organ donation programs. Additionally, the U.S. transplantation market is projected to reach USD 8.54 billion by 2032, driven by increasing organ donation rates and technological advancements.

Market Drivers

A key factor driving market growth is the increasing demand for transplantation procedures worldwide. The rising prevalence of chronic conditions such as cancer, kidney failure, chronic obstructive pulmonary disease (COPD), and lupus has significantly increased organ failure cases.

For instance, according to the U.S. Health Resources & Services Administration, over 103,000 individuals were on the U.S. national organ transplant waiting list in February 2024. Furthermore, in 2023, more than 46,000 organ transplant procedures were performed in the U.S., highlighting strong procedural demand.

In addition, government and non-government initiatives promoting organ donation awareness are boosting market expansion. Organizations such as ORGAN India and the National Health Service (NHS) in the U.K. actively run campaigns encouraging donor registration, thereby increasing transplantation rates.

COVID-19 Impact

The COVID-19 pandemic negatively impacted the transplantation market, particularly during 2020, due to reduced elective procedures, strict safety guidelines, and fewer hospital visits. Transplant procedures declined globally, affecting the sales of key market players.

However, the market gradually recovered by the end of 2022, as hospital operations resumed and awareness regarding organ donation increased. Strategic research initiatives and new product launches helped the market return to its pre-pandemic growth trajectory by 2024, supporting stable growth during 2025-2032.

Market Trends

One of the major trends shaping the transplantation market is the increase in collaborations between public and private stakeholders. These collaborations aim to improve organ donation rates, enhance transplant infrastructure, and streamline donor-recipient matching processes.

For example, the Transplant Therapeutics Consortium (TTC) collaborates with industry players, academic institutions, and regulatory agencies to accelerate transplant-related innovations. Similarly, international collaborations involving organizations such as PAHO and the Government of Spain are strengthening transplant ecosystems across regions.

Growth Factors

Another significant growth driver is the advancement in tissue engineering and preservation technologies. Innovations such as 3D bioprinting, stem cell-based tissue regeneration, and xenotransplantation are addressing donor shortages and reducing rejection risks.

For instance, in June 2023, 3D BioFibR launched novel collagen-based bio-ink products for tissue and organ bioprinting. These technological advancements are expanding treatment possibilities and supporting long-term market growth.

Restraining Factors

Despite strong growth prospects, the market faces challenges due to prolonged waiting periods for transplant procedures. According to Donate Life America, one person is added to the U.S. transplant waiting list every 8 minutes, and the average waiting time for kidney transplantation ranges from 3 to 5 years.

In developing countries, limited awareness, inadequate reimbursement policies, and insufficient transplant infrastructure further restrict market growth. These factors continue to act as barriers to widespread adoption.

Segmentation Analysis

• By Product Type: The immunosuppressive drugs segment dominated the market with a 43.18% share in 2026, owing to their essential role in preventing organ rejection.
• By Application: The tissue transplantation segment held a 63.88% market share in 2026, driven by the high volume of procedures such as corneal and skin transplants.
• By End-user: Hospitals led the market with a 60.06% share in 2026, as they remain primary centers for complex transplant procedures.

Regional Insights

North America accounted for USD 5.04 billion in 2025 and continues to dominate due to advanced technologies and strong regulatory support. Europe holds the second-largest share, supported by awareness initiatives and increasing procedures. Asia Pacific is witnessing rapid growth due to rising chronic disease prevalence and improving healthcare infrastructure, particularly in China, Japan, and India.

Competitive Landscape

The market is moderately fragmented, with leading players such as Zimmer Biomet, Astellas Pharma, BioLife Solutions, Novartis AG, TransMedics, and Roche. These companies focus on product innovation, strategic partnerships, and acquisitions to strengthen their market position.

Conclusion

In conclusion, the global transplantation market is expected to grow from USD 11.93 billion in 2025 to USD 28.57 billion by 2034, driven by rising organ failure cases, increasing transplant procedures, supportive government initiatives, and continuous technological advancements. While challenges such as donor shortages and long waiting periods persist, expanding awareness programs, innovation in tissue engineering, and strong collaboration among stakeholders are expected to sustain robust market growth throughout the forecast period.

Segmentation By Product Type

• Tissue Products
• Immunosuppressive Drugs
• Preservation Solutions

By Application

• Organ Transplantation
• Tissue Transplantation

By End-user

• Hospitals
• Transplantation Centers
• Others

By Region

• North America (By Product Type, Application, End-user, and Country/Sub-Region)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Product Type, Application, End-user, and Country/Sub-Region)
  • Germany (By Application)
  • France (By Application)
  • U.K. (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Product Type, Application, End-user, and Country/Sub-Region)
  • China (By Application)
  • Japan (By Application)
  • India (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Product Type, Application, End-user, and Country/Sub-Region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Product Type, Application, End-user, and Country/Sub-Region)
  • GCC (By Application)
  • South Africa (By Application)
  • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Major Organ Transplantation, By Key Countries, 2025
• 4.2. Key Industry Developments- Mergers, Acquisitions and Partnerships
• 4.3. Overview of Regulatory Scenario
• 4.4. Impact of COVID-19 on the Market

5. Global Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Tissue Products
  • 5.1.2. Immunosuppressive Drugs
  • 5.1.3. Preservation Solutions
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Organ Transplantation
  • 5.2.2. Tissue Transplantation
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Transplantation Centers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Tissue Products
  • 6.1.2. Immunosuppressive Drugs
  • 6.1.3. Preservation Solutions
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Organ Transplantation
  • 6.2.2. Tissue Transplantation
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Transplantation Centers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Tissue Products
  • 7.1.2. Immunosuppressive Drugs
  • 7.1.3. Preservation Solutions
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Organ Transplantation
  • 7.2.2. Tissue Transplantation
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Transplantation Centers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
    • 7.4.1.1. By Application
  • 7.4.2. France
    • 7.4.2.1. By Application
  • 7.4.3. U.K.
    • 7.4.3.1. By Application
  • 7.4.4. Italy
    • 7.4.4.1. By Application
  • 7.4.5. Spain
    • 7.4.5.1. By Application
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Application
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Application

8. Asia Pacific Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Tissue Products
  • 8.1.2. Immunosuppressive Drugs
  • 8.1.3. Preservation Solutions
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Organ Transplantation
  • 8.2.2. Tissue Transplantation
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Transplantation Centers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
    • 8.4.1.1. By Application
  • 8.4.2. Japan
    • 8.4.2.1. By Application
  • 8.4.3. India
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Tissue Products
  • 9.1.2. Immunosuppressive Drugs
  • 9.1.3. Preservation Solutions
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Organ Transplantation
  • 9.2.2. Tissue Transplantation
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Transplantation Centers
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Transplantation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Tissue Products
  • 10.1.2. Immunosuppressive Drugs
  • 10.1.3. Preservation Solutions
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Organ Transplantation
  • 10.2.2. Tissue Transplantation
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Transplantation Centers
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
    • 10.4.1.1. By Application
  • 10.4.2. South Africa
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Novartis AG
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Arthrex, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Veloxis Pharmaceuticals, Inc. (Asahi Kasei Corporation)
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. BioLife Solutions
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. TransMedics
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. F. Hoffmann-La Roche Ltd
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Zimmer Biomet
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Astellas Pharma Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)